首页> 美国政府科技报告 >Identifying Therapeutics for Platinum-Resistant Ovarian Cancer by Next Generation Mechanotyping.

【24h】

Identifying Therapeutics for Platinum-Resistant Ovarian Cancer by Next Generation Mechanotyping.

机译：通过下一代机械分型鉴定抗铂类卵巢癌的治疗方法。

获取原文

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Rowat, A.;
展开▼
作者单位

展开▼
年度 2017
页码 1-18
总页数 18
原文格式 PDF
正文语种 eng
中图分类
关键词
Therapeutics; Platinum-Resistant Ovarian Cancer;

机译：治疗学;抗白斑的卵巢癌;

相似文献

外文文献
中文文献
专利

1. Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin--an evaluation of the therapeutic index with special emphasis on cardiac toxicity. [J] . Steppan I, Reimer D, Sevelda Chemotherapy: International Journal of Experimental and Clinical Chemotherapy . 2009,第6期

机译：聚乙二醇化阿霉素治疗复发的铂耐药性卵巢癌-评价治疗指数，特别强调心脏毒性。
2. An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023 [J] . Tadahiro Shoji, Shinichi Komiyama, Junzo Kigawa, BMC Cancer . 2018,第1期

机译：在铂抗性上皮卵巢卵巢卵巢卵巢卵巢卵巢，输卵管或原发性腹膜癌症患者中使用Bevacizumab用于前线或铂敏感的抗蜂巢蛋白，或没有Bevacizumab的疗效和安全性评估患者的疗效和安全性卵巢癌：日本妇科肿瘤学群体研究JGOG3023的理由，设计和方法
3. Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. [J] . Sehouli J, Stengel D, Harter P, Journal of Clinical Oncology . 2011,第2期

机译：铂耐性卵巢癌患者的拓扑替康每周与常规5天时间表的比较：东北德国妇科肿瘤学会卵巢癌研究组的一项随机多中心II期临床试验。
4. Profiling of Ovarian Cancer Reveals Common Features Shared by Sub-types of Ovarian Cancer: A network biology approach towards finding therapeutic drug targets [C] . Rinki Singh, Anup Som International Conference on Bioinformatics and Systems Biology . 2018

机译：剖析卵巢癌揭示了卵巢癌亚型共有的共同特征：寻找治疗药物靶点的网络生物学方法
5. Use of a transgenic mouse model of ovarian hyperstimulation to identify therapeutic targets and mechanisms in hormone-induced mammary cancer. [D] . Milliken, Erin Lee. 2005

机译：卵巢过度刺激转基因小鼠模型在荷尔蒙诱导的乳腺癌中鉴定治疗靶点和机制的用途。
6. An open-label randomized phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian fallopian tube or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale design and methods of the Japanese Gynecologic Oncology Group study JGOG3023 [O] . Tadahiro Shoji, Shinichi Komiyama, Junzo Kigawa, 2018

机译：一项开放性随机II期临床试验评估接受或不接受贝伐单抗治疗的标准治疗在铂耐药的上皮性卵巢癌输卵管或原发性腹膜癌患者中接受过贝伐单抗治疗的一线或铂类敏感性的疗效和安全性卵巢癌：日本妇科肿瘤小组研究JGOG3023的原理设计和方法
7. An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023 [O] . Tadahiro Shoji, Shinichi Komiyama, Junzo Kigawa, 2018

机译：在铂抗性上皮卵巢卵巢卵巢卵巢卵巢卵巢，输卵管或原发性腹膜癌症患者中使用Bevacizumab用于前线或铂敏感的抗蜂巢蛋白，或没有Bevacizumab的疗效和安全性评估患者的疗效和安全性卵巢癌：日本妇科肿瘤学群体研究JGOG3023的理由，设计和方法

Identifying Therapeutics for Platinum-Resistant Ovarian Cancer by Next Generation Mechanotyping.

著录项

引文网络

相似文献

相关主题

期刊订阅